SHANGHAI – When Beyondspring Pharmaceuticals Inc., a clinical-stage immuno-oncology biopharma started its U.S.-China development strategy for lead candidate plinabulin, getting a first-in-class drug past China's regulators was an unwieldy prospect, often taking years longer than the U.S. But after China's most recent round of regulatory reforms, things are looking up considerably.